Comparative effectiveness and safety of <em>nab</em>-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting

• DOI: 10.2147/lctt.s139647
• Publication Date: 2017-10-20T01:11:02Z
• Authors: Raja Mudad; Manish B Patel; Sandra Margunato-...; David Garofalo; Lincy S Lal
• Keywords: Carboplatin

Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab -paclitaxel plus carboplatin vs gemcitabine platinum were analyzed in patients with advanced or metastatic squamous cell non-small lung cancer (NSCLC). Materials methods: Patients who received ≥ 1 cycle first-line identified from the Navigating Cancer database. Clinical effectiveness endpoints included overall survival (OS) time to treatment discontinuation (TTD). Other safety utilization care. Cox proportional hazards models used control for potential confounding effects baseline characteristics. Results: In total, 193 ( carboplatin, n = 61; platinum, 132). Baseline characteristics generally similar between cohorts. receiving had a significantly longer OS than those (median, 12.8 9.0 months; P 0.03). However, adjusted difference was not statistically significant (adjusted HR 1.55; 95% CI, 0.99–2.42; 0.06). -Paclitaxel carboplatin-treated TTD 4.3 3.5 0.03; 1.39; 1.01–1.90; 0.04). Grade 3 4 anemia neutropenia lower treated carboplatin. Nausea neuropathy (grade specified) higher group. No differences observed Conclusion: These real-world data support NSCLC. Keywords: chemotherapy, doublet options, electronic medical records, NSCLC, evidence, retrospective analysis